Iparomlimab (QL1604) in Patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dmmr) Unresectable or Metastatic Solid Tumors: a Pivotal, Single-Arm, Multicenter, Phase II Trial

Feng Bi, Jian Dong,Chuan Jin,Zuoxing Niu, Wenhui Yang, Yifu He, Dajun Yu, Meili Sun,Teng Wang,Xianli Yin, Ruixing Zhang, Kehe Chen,Keming Wang, Zhiwu Wang,Wei Li,Zhongtao Zhang, Hangyu Zhang, Qunyi Guo, Xin Wang, Lei Han,Xizhi Zhang, Wei Shen, Liangming Zhang, Jieer Ying,Miao Wu, Weiguo Hu,Zeng Li, Xiaofen Li, Wenlei Feng, Baihui Zhang, Lingyan Li, Xiaoyan Kang, Weijian Guo

Journal of Hematology & Oncology（2024）

引用 0|浏览0

暂无评分

关键词

Iparomlimab (QL1604),MSI-H/dMMR,PD-1,Solid tumors,Immunotherapy,Colorectal cancer,Liver metastasis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要